Technical Analysis for ADXS - Advaxis, Inc.

Grade Last Price % Change Price Change
C 0.8399 -4.88% -0.04
ADXS closed down 4.88 percent on Friday, February 26, 2021, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 11
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical ADXS trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish -4.88%
Wide Bands Range Expansion -4.88%
Crossed Above 20 DMA Bullish -16.84%
Wide Bands Range Expansion -16.84%
Fell Below 20 DMA Bearish -4.49%
MACD Bearish Signal Line Cross Bearish -4.49%
Older End-of-Day Signals for ADXS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Up 3% 1 day ago
Up 2% 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Advaxis, Inc. Description

Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company's platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The company's products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Infectious Diseases Cancers Prostate Cancer Tumor Immunotherapies Sarcoma Infectious Causes Of Cancer Therapies For Cancer Her2 Platform Technology Head And Neck Cancer Immune Response Cancer Vaccine Cervical Cancer HPV Human Papillomavirus Infection Osteosarcoma Anal Cancer Mdsc

Is ADXS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.57
52 Week Low 0.2639
Average Volume 15,473,924
200-Day Moving Average 0.56
50-Day Moving Average 0.71
20-Day Moving Average 1.00
10-Day Moving Average 1.07
Average True Range 0.15
ADX 55.43
+DI 30.80
-DI 21.91
Chandelier Exit (Long, 3 ATRs ) 1.13
Chandelier Exit (Short, 3 ATRs ) 1.10
Upper Bollinger Band 1.37
Lower Bollinger Band 0.63
Percent B (%b) 0.28
BandWidth 73.83
MACD Line 0.07
MACD Signal Line 0.12
MACD Histogram -0.0487
Fundamentals Value
Market Cap 92.24 Million
Num Shares 110 Million
EPS -4.09
Price-to-Earnings (P/E) Ratio -0.21
Price-to-Sales 60.17
Price-to-Book 0.96
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.97
Resistance 3 (R3) 0.98 0.94 0.95
Resistance 2 (R2) 0.94 0.91 0.94 0.94
Resistance 1 (R1) 0.89 0.89 0.87 0.88 0.93
Pivot Point 0.86 0.86 0.85 0.85 0.86
Support 1 (S1) 0.81 0.82 0.79 0.80 0.75
Support 2 (S2) 0.77 0.80 0.77 0.74
Support 3 (S3) 0.72 0.77 0.73
Support 4 (S4) 0.71